Invega Sustenna, also known by its generic name paliperidone palmitate, is an injectable antipsychotic medication used to treat schizophrenia and schizoaffective disorder [1][2]. It is a long-acting injectable (LAI) formulation of paliperidone [1][2].
How does Invega Sustenna work?
Invega Sustenna delivers paliperidone palmitate, which is converted to paliperidone in the body [1]. Paliperidone is an atypical antipsychotic that works by blocking dopamine D2 and serotonin 5-HT2A receptors in the brain [3]. By modulating these neurotransmitters, it helps to reduce symptoms of psychosis, such as hallucinations and delusions, and improve thought processes [3].
When was Invega Sustenna first approved?
Invega Sustenna was approved by the U.S. Food and Drug Administration (FDA) in 2009 [4].
How often is Invega Sustenna administered?
Invega Sustenna is administered as an intramuscular injection once every month [1][2]. Dosing can be initiated with different strengths depending on the specific needs of the patient [1].
What are the advantages of using Invega Sustenna?
As a long-acting injectable, Invega Sustenna offers an advantage in adherence to treatment, as it eliminates the need for daily oral medication [1][5]. This can be particularly beneficial for individuals who have difficulty remembering to take their medication or prefer not to take daily pills [5]. The monthly administration can help maintain consistent therapeutic levels of the medication, potentially leading to better symptom control and reduced relapse rates [5].
What is the difference between Invega Sustenna and Invega?
Invega Sustenna is the long-acting injectable form of paliperidone, while Invega (oral) is the immediate-release tablet formulation of the same active ingredient [1][6]. Invega Sustenna is designed for monthly administration, whereas Invega tablets are taken daily [1][6].
Are there other long-acting paliperidone formulations?
Yes, there is also Invega Trinza, which is an extended-release injectable formulation of paliperidone palmitate administered every three months [7]. Another formulation, Invega Hafyera, allows for administration every six months [7].
What side effects can occur with Invega Sustenna?
Common side effects of Invega Sustenna can include injection site reactions, headache, and weight gain [1]. Other potential side effects may involve movement disorders such as akathisia (restlessness), extrapyramidal symptoms, and tardive dyskinesia, as well as hormonal changes leading to increased prolactin levels [1][3]. It is important for patients to discuss any concerns about side effects with their healthcare provider [1].
When does the patent for Invega Sustenna expire?
Information on specific patent expiry dates for Invega Sustenna is available through resources like DrugPatentWatch.com [8]. Patent protection is crucial for the exclusivity of branded medications, and its expiration typically opens the door for generic competition [8].
Can generic versions of Invega Sustenna be developed?
Yes, once patent protections expire and regulatory hurdles are cleared, generic manufacturers can develop and market bioequivalent versions of Invega Sustenna [8]. The development of generic injectables can involve complex manufacturing processes to ensure the drug's stability, efficacy, and safety are comparable to the branded product.